US5441964A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for inhibiting bone loss using substituted benzothiophene
Assignee: Eli Lilly and Co
•
Filing: 1993-10-15
•
Granted: 1995-08-15
•
Expires: 2013-10-15
Abstract
Abstract A method of inhibiting bone loss comprising administering to a human in need of treatment an effective amount of a substituted benzothiophene.
Inventors
- 👤 Henry U. Bryant
- 👤 Timothy A. Grese
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:28
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/38; A61K31/381; A61K31/395; A61K31/435; A61K31/47; A61K31/40; A61K31/4025; A61K31/44; A61K31/445; A61K31/4523; A61K31/4535; A61K31/535; A61P; A61P43/00; C; C07; C07D; C07D333/00; C07D333/50; C07D333/52; C07D333/54; C07D333/56; C07D409/00; C07D409/02; C07D409/10
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
326 words
A method of inhibiting bone loss comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR11## wherein R is hydrogen; hydroxy; C 1 -C 6 alkoxy; a group of the formula --O--C(O)--R a , wherein R a is hydrogen, C 1 -C 6 alkyl optionally substituted with amino, halo, carbonyl, C 1 -C 6 alkoxycarbonyl, C 1 -C 7 alkanoyloxy, carbamoyl and/or aryl; or R a is C 1 -C 6 alkenyl optionally substituted with aryl; or R a is a C 3 -C 7 cycloalkyl; or R a is aryl optionally substituted with hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and/or halo; or R a is --O--aryl, said aryl optionally substituted with hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and/or halo, or R is a group of the formula --O--SO 2 --R b wherein R b may be C 1 -C 6 alkyl or aryl optionally substituted with C 1 -C6 alkyl; or R is carbamoyloxy wherein the nitrogen may be substituted once or twice with C 1 -C6 alkyl; or R is a group of the formula --O--C(O)R c --O--(C 1 -C 6 alkyl) wherein R c is a bond or C 1 -C 6 alkanediyl; R 1 is halo, C 1 -C 6 alkyl, C 1 -C 7 alkyl substituted with C 1 -C 6 alkyl, substituted or unsubstituted C 3 -C 7 cycloalkyl, or substituted or unsubstituted C 3 -C 7 cycloalkenyl; R 2 is O or CH 2 ; R 3 is CH 2 or (CH 2 ) 2 ; R 4 is ##STR12## CH 2 , or a bond; and R 5 is amino, nitrilo optionally substituted once or twice with C 1 -C 6 alkyl; or an N-heterocyclic ring which optionally has another hetero atom selected from N, O or S in said ring; or a pharmaceutically acceptable salt or solvate thereof.
Claim 2
Independent Claim
326 words
A method of inhibiting bone loss comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR11## wherein R is hydrogen; hydroxy; C 1 -C 6 alkoxy; a group of the formula --O--C(O)--R a , wherein R a is hydrogen, C 1 -C 6 alkyl optionally substituted with amino, halo, carbonyl, C 1 -C 6 alkoxycarbonyl, C 1 -C 7 alkanoyloxy, carbamoyl and/or aryl; or R a is C 1 -C 6 alkenyl optionally substituted with aryl; or R a is a C 3 -C 7 cycloalkyl; or R a is aryl optionally substituted with hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and/or halo; or R a is --O--aryl, said aryl optionally substituted with hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkoxy, and/or halo, or R is a group of the formula --O--SO 2 --R b wherein R b may be C 1 -C 6 alkyl or aryl optionally substituted with C 1 -C6 alkyl; or R is carbamoyloxy wherein the nitrogen may be substituted once or twice with C 1 -C6 alkyl; or R is a group of the formula --O--C(O)R c --O--(C 1 -C 6 alkyl) wherein R c is a bond or C 1 -C 6 alkanediyl; R 1 is halo, C 1 -C 6 alkyl, C 1 -C 7 alkyl substituted with C 1 -C 6 alkyl, substituted or unsubstituted C 3 -C 7 cycloalkyl, or substituted or unsubstituted C 3 -C 7 cycloalkenyl; R 2 is O or CH 2 ; R 3 is CH 2 or (CH 2 ) 2 ; R 4 is ##STR12## CH 2 , or a bond; and R 5 is amino, nitrilo optionally substituted once or twice with C 1 -C 6 alkyl; or an N-heterocyclic ring which optionally has another hetero atom selected from N, O or S in said ring; or a pharmaceutically acceptable salt or solvate thereof.
Claim 3
Dependent Claim
11 words
A method of claim 1 wherein the human is a female.
Claim 4
Dependent Claim
11 words
A method of claim 2 wherein the female is estrogen deficient.
Claim 5
Dependent Claim
10 words
A method of claim 3 wherein the female is post-menopausal.
Claim 6
Dependent Claim
40 words
A method according to claim 1 wherein R 1 is a group having the formula ##STR13## or a cycloalkyl group with a carbon number of three to eight that may be substituted with C 1 -C 6 alkyl or hydroxy.
Claim 7
Dependent Claim
9 words
A method of claim 5 wherein R is hydroxy.
Claim 8
Dependent Claim
18 words
A method according to claim 6 wherein R 2 is O and R 4 is CH 2 .
Claim 9
Dependent Claim
17 words
The method according to claim 1 wherein said compound is (6-hydroxy-2-cyclohexylbenzo[b]thien-3-yl)[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, (6-hydroxy-2-cyclohexylbenzo[b]thien-3-yl)[4-[2-(1piperidinyl)ethoxy]phenyl]methanone, (6-hydroxy-2-cycloheptylbenzo[b]thien-3-yl)[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, (6-hydroxy-2-cycloheptylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone, (6-hydroxy-2-isopropylbenzo[b]thien-3-yl)[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methanone, or (6-hydroxy-2-isopropylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone.
Claim 10
Dependent Claim
13 words
The method according to claim 6 wherein R 2 is CH 2 .
Claim 11
Dependent Claim
14 words
The method according to claim 9 wherein said compound is (6-hydroxy-2-cyclohexylbenzo[b]thien-3-yl)[4-[3-(1-pyrrolidinyl)propyl]phenyl]methanone, (6-hydroxy-2cyclohexylbenzo[b]thien-3-yl)[4-[3-(1-piperidinyl)propyl]phenyl]methanone, or (6-hydroxy-2cyclohexylbenzo[b]thien-3-yl)[4-[2-(1-pyrrolidinylcarbonyl)ethyl]phenyl]methanone.
Claim 12
Dependent Claim
14 words
The method according to claim 5 wherein R is C 1 -C 6 alkoxy.
Claim 13
Dependent Claim
13 words
The method according to claim 11, wherein said compound is (6-methoxy-2-cyclohexylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone or (6-acetoxy-2-cyclohexylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-08-14 | 1999-02-13 | 1999-08-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-08-14 | 2003-02-13 | 2003-08-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-08-14 | 2007-02-13 | 2007-08-15 | $7700.00 | Window Closed / Lapsed |